Samus Therapeutics, Inc.
8 clinical trials · Sponsor
◉ Watch Samus Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis (NCT04505358) | Samus Therapeutics, Inc. | 2023-01-01 |
| A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN (NCT05612633) | Samus Therapeutics, Inc. | 2022-06-15 |
| Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma (NCT04782609) | Samus Therapeutics, Inc. | 2021-12-27 |
| Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib (NCT03935555) | Samus Therapeutics, Inc. | 2019-08-12 |
| A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects (NCT03935568) | Samus Therapeutics, Inc. | 2019-06-24 |
| Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis (NCT03373877) | Samus Therapeutics, Inc. | 2018-05-24 |
Track Samus Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.